PMID- 25600779
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20161230
IS  - 1827-1618 (Electronic)
IS  - 0026-4725 (Linking)
VI  - 63
IP  - 1
DP  - 2015 Feb
TI  - The TITAN-AMI multicenter registry evaluating the usage of Titan2 stent in 
      patients with ST segment elevation myocardial infarction. Final result at 
      12-month follow-up.
PG  - 11-20
AB  - AIM: Primary percutaneous coronary intervention with stent implantation is the 
      recommended treatment for patients with ST elevation myocardial infarction 
      (STEMI). Data from randomised trials showed good performance by a 
      titanium-nitric-oxide coated stent in this context. The aim of this study was to 
      confirm these data. METHODS: A multicentre registry was compiled in 23 hospitals 
      in Spain in an all-comers population. We selected patients with STEMI from a 
      global Titan AMI registry that included patients with acute coronary syndrome. 
      Primary endpoint was the composite of cardiac death, non-fatal myocardial 
      infarction, stent thrombosis and target lesion revascularisation, at 12-month 
      follow-up. RESULTS: The study included 893 patients with STEMI. We included all 
      possibilities for PCI: 86.6% primary, 5% facilitated after successful 
      fibrinolysis and 8.4% rescue PCI after failed fibrinolysis. The primary endpoint 
      was reached in 8.4% of the patients: cardiac death 2.7%, reinfarction 3.4%, 
      target lesion revascularisation 3.5% and definite or probable stent thrombosis 
      2.8%. The majority of stent thromboses presented in the first 30 days after PCI. 
      CONCLUSION: A bioactive stent (titanium-nitric-oxide coated stent) is a possible 
      alternative for the treatment of patients with STEMI. One-year follow-up showed 
      better results than those presented by a regular bare-metal stent or 
      first-generation drug-eluting stent in terms of stent thrombosis.
FAU - Gomez-Hospital, J A
AU  - Gomez-Hospital JA
FAU - Mauri, J
AU  - Mauri J
FAU - Pinar, E
AU  - Pinar E
FAU - Goicolea, J
AU  - Goicolea J
FAU - Garcia Del Blanco, B
AU  - Garcia Del Blanco B
FAU - Serra, A
AU  - Serra A
FAU - Tizon-Marcos, H
AU  - Tizon-Marcos H
FAU - Molina, E
AU  - Molina E
FAU - Sanchez, E
AU  - Sanchez E
FAU - Aragon, V
AU  - Aragon V
FAU - Masotti, M
AU  - Masotti M
FAU - Rodriguez, J
AU  - Rodriguez J
FAU - Jimenez, J
AU  - Jimenez J
FAU - Ortas, R
AU  - Ortas R
FAU - Martinez, P
AU  - Martinez P
FAU - Serra, B
AU  - Serra B
FAU - Moreu, J
AU  - Moreu J
FAU - Diego Nieto, G
AU  - Diego Nieto G
FAU - Bossa, F
AU  - Bossa F
FAU - Nogales, J M
AU  - Nogales JM
FAU - Bassaganyas, J
AU  - Bassaganyas J
FAU - Diaz, J
AU  - Diaz J
FAU - Cascon, J D
AU  - Cascon JD
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Italy
TA  - Minerva Cardioangiol
JT  - Minerva cardioangiologica
JID - 0400725
RN  - 0 (titanium-nitride-oxide)
RN  - D1JT611TNE (Titanium)
SB  - IM
MH  - Acute Coronary Syndrome/*surgery
MH  - Aged
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*surgery
MH  - Percutaneous Coronary Intervention/*methods
MH  - Registries
MH  - Spain
MH  - *Stents
MH  - Thrombosis/epidemiology/etiology
MH  - Time Factors
MH  - Titanium/chemistry
MH  - Treatment Outcome
EDAT- 2015/01/21 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/01/21 06:00
PHST- 2015/01/21 06:00 [entrez]
PHST- 2015/01/21 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - R05Y9999N00A150002 [pii]
PST - ppublish
SO  - Minerva Cardioangiol. 2015 Feb;63(1):11-20.